title: [Efficacy and tolerance of tenofovir-lamivudine-efavirenz combination in HIV-1 patients in Fann Teaching Hospital in Dakar].
abstract: We conducted a study to evaluate the efficacy and tolerance of the tenofovir (TDF), lamivudine (3TC) and efavirenz (EFV) combination regimen in HIV-1 patients by a descriptive analytical retrospective study of all HIV-1 patients receiving TDF-3TC-EFV combination between 2007 and 2011. Collected data was analysed using EpiInfo™ version 6.04. One hundred patients were included, with an average follow-up duration of 27 months and 19 days (± 21 months and 14 days).We observed an average increase in body weight of about 8 kg per annum, with an average rise in CD4 count of 100/mm(3) by the end of the second year. A reduction in viral load with 71% of patients in therapeutic success at 24 month of treatment was noted. Ninety-two patients presented with at least one side effect, mostly being Grade 1 or 2 (96.36%). Neurological (24 patients) and digestive (20 patients) complaints comprised the commonest reported side effects. Four patients had adverse effects severe enough to warrant a change in treatment regimen, principally due to renal insufficiency. Thirteen subjects died. Patients receiving TDF-3TC-EVF combination therapy need rigorous surveillance because this combination, although efficient, is not without significant adverse effects.
authors.affiliation: Service des maladies infectieuses, Centre Hospitalier National Universitaire de Fann, Dakar, Sénégal.
authors.forename: S A
authors.initials: SA
authors.lastname: Diop
authors.forename: L
authors.initials: L
authors.lastname: Fortes-Déguénonvo
authors.forename: M
authors.initials: M
authors.lastname: Seydi
authors.forename: A B
authors.initials: AB
authors.lastname: Dieng
authors.forename: C D
authors.initials: CD
authors.lastname: Basse
authors.forename: N M
authors.initials: NM
authors.lastname: Manga
authors.forename: N M
authors.initials: NM
authors.lastname: Dia
authors.forename: G
authors.initials: G
authors.lastname: Ndaw
authors.forename: C T
authors.initials: CT
authors.lastname: Ndour
authors.forename: M
authors.initials: M
authors.lastname: Soumaré
authors.forename: B M
authors.initials: BM
authors.lastname: Diop
authors.forename: P S
authors.initials: PS
authors.lastname: Sow
mesh_terms: D000225:Adenine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D000328:Adult; D000480:Alkynes; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects; D048588:Benzoxazines / Q000008:administration & dosage* / Q000009:adverse effects*; D003521:Cyclopropanes; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000453:epidemiology; D015497:HIV-1 / Q000187:drug effects / Q000502:physiology; D006784:Hospitals, Teaching / Q000706:statistics & numerical data; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage* / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D063065:Organophosphonates / Q000008:administration & dosage* / Q000009:adverse effects*; D012189:Retrospective Studies; D012675:Senegal / Q000453:epidemiology; D000068698:Tenofovir; D016896:Treatment Outcome
chemical_list: D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D063065:Organophosphonates; D019259:Lamivudine; D000068698:Tenofovir; D000225:Adenine; C098320:efavirenz